Acceleron Pharma Inc.
If you purchased Acceleron Pharma Inc. securities and would like to join the action, please click "Join This Action" below.
ACCELERON MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF ACCELERON PHARMA INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – XLRN
September 30, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Acceleron Pharma Inc. (NASDAQ: XLRN) to Merck & Co., Inc. for $180.00 per share in cash is fair to Acceleron shareholders.
The investigation concerns whether Acceleron and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Acceleron shareholders; (2) determine whether Merck is underpaying for Acceleron; and (3) disclose all material information necessary for Acceleron shareholders to adequately assess and value the merger consideration. On behalf of Acceleron shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.